According to reports from Business Upturn, Alivus Life Sciences Limited has completed the acquisition of a 76% stake in IQGEN-X Pharma Private Limited for a consideration of ₹9.12 crores. The transaction involves the acquisition of 8,60,589 equity shares, each with a face value of ₹10, representing 76% of the paid-up equity share capital of IQGEN-X Pharma Private Limited. The deal was approved by the board on August 18, 2026, with the consideration subject to customary adjustments as outlined in the Share Purchase Agreement. The transaction is subject to customary closing conditions and is expected to conclude by December 6, 2026, or another mutually agreed upon date.
As reported by Business Standard, IQGEN-X Pharma was founded in October 2016 and operates as a custom research organization specializing in formulation development. The company focuses on oral solids, sterile injectable and ophthalmic solutions for highly regulated markets including the US, EU, Latin America, Middle East and other semi-regulated regions. The company's turnover has shown consistent growth over the last three financial years: ₹267.5 lakhs in 2023-24, ₹318.2 lakhs in 2024-25, and projected ₹348.0 lakhs for 2025-26. This acquisition allows Alivus Life Sciences, which primarily focuses on Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, to bolster its formulation development capabilities through IQGEN-X's specialized platform.
According to Business Upturn, the acquisition creates an integrated end-to-end platform that delivers deep scientific expertise across complex delivery formats including oral solids, complex injectables and ophthalmics. Through the IQGEN-X platform, Alivus extends its operational footprint to include rigorous bioequivalence and stability studies, thereby enabling comprehensive regulatory filings tailored for diverse global markets. The platform will cover pre-formulation studies, prototype development, process optimisation, seamless scale-up, clinical supplies and full-scale commercial manufacturing. These services will be complemented with analytical development, methods validation, stability programmes and complete regulatory submission support. The combined entity will offer comprehensive scientific expertise across complex delivery formats, including oral solids, complex injectables, and ophthalmics.
As reported by Business Upturn, Alivus is significantly scaling up its value proposition for global CDMO customers through this expanded service platform. The acquisition signifies a strategic expansion for Alivus Life Sciences within the pharmaceutical industry, providing the company with a wider spectrum of offerings, enabling it to deliver a complete end-to-end solution to its customers in both the Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organization (CDMO) spaces. The transaction does not involve related party dealings, and no promoter has any interest in the entity being acquired, ensuring it is conducted at arm's length. Through this business expansion, Alivus aims to provide an integrated platform offering enhanced services to Contract Development and Manufacturing Organisation (CDMO) customers worldwide.
According to Business Upturn, Alivus will strategically leverage IQGEN-X's specialized platform alongside its own world-class API portfolio, with primary focus on Oncology. The company intends to focus on strategic out-licensing and expanding its portfolio in oncology, thereby positioning itself as a significant asset provider by leveraging both its new acquisition and its existing API capabilities. This combination creates a high-impact basket of differentiated, niche assets for the company's pharmaceutical portfolio, with the company maintaining a diversified portfolio that spans multiple continents including North America, Europe, Japan, and India. The assets will be backed by validated, commercial-scale manufacturing capabilities, with the company serving customers across India, Europe, North America, Latin America, Japan, and the Rest of the World.
